Dessau-Roßlau
- Jul 5
Merz invests over €100 million in Dessau-Roßlau as botulinum toxin demand surges
The German pharmaceutical company Merz is investing more than 100 million euros in its Dessau-Roßlau site to expand production of its botulinum toxin product Xeomin, driven by rising medical and aesthetic demand.
- Jun 14
Saxony-Anhalt CDU pledges pharma hub and more police, rules out AfD coalition
Three months before Saxony-Anhalt's state vote, CDU delegates unanimously approved a platform focusing on the economy, internal security and education. A photo of a CDU and AfD politician at a shared microphone has overshadowed the convention.
